Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps

Clinical Infectious Diseases

Volumn 30, Issue 1, 2000, Pages 157-164

  Pepper, Patricia Vold ^a   Owens, Douglas K ^b,c,d  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HEALTH ECONOMICS; HEALTH STATUS; HUMAN; LIFE EXPECTANCY; LOBAR PNEUMONIA; MODEL; NAVY; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINATION;

ADULT; BACTERIAL VACCINES; COST-BENEFIT ANALYSIS; DECISION MAKING, COMPUTER-ASSISTED; HUMANS; MARKOV CHAINS; MILITARY PERSONNEL; PNEUMOCOCCAL INFECTIONS; QUALITY-ADJUSTED LIFE YEARS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINATION;

EID: 0033956626     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313601     Document Type: Article

References (57)

1. Fedson D, Musher D. Pneumococcal vaccine. In: Plotkin S, Mortimer E, eds. Vaccines. Philadelphia: WB Saunders, 1994:517-64.
2. Woodhead M, Macfarlane J, McCracken J, Rose D, Finch R. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987; 1:671-4.
3. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 1997:46:1-24.
4. Fang G, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. Medicine 1990; 69:307-16.
5. Karalus N, Cursons R, Leng R, et al. Community acquired pneumonia: aetiology and prognostic index evaluation. Thorax 1991; 46:413-8.
6. Macfarlane J, Finch R, Ward M, Macrae A. Hospital study of adult community-acquired pneumonia. Lancet 1982; 2:255-8.
7. Marston B, Plouffe J, File T, et al. Incidence of community-acquired pneumonia requiring hospitalization. Arch Intern Med 1997; 157:1709-18.
8. Harrison B, Farr B, Pugh D, Selkon J, Prescott R, Connolly C. Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome. Q J Med 1987; 62:195-200.
9. Pazzaglia G, Pasternack M. Recent trends of pneumonia morbidity in U.S. naval personnel. Mil Med 1983; 148:647-51.
10. Reichler M, Reynolds R, Schwartz B, et al. Epidemic of pneumococcal pneumonia at a military training camp [abstract 49]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 1991:107.
11. Gray G, Mitchell B, Tueller J, Cross E, Amundson D. Pneumonia hospitalizations in the U.S. Navy and Marine Corps: rates and risk factors for 6,522 admissions, 1981-1991. Am J Epidemiol 1994; 139:793-802.
12. Centers for Disease Control and Prevention. Recommendations of the Immunization Practices Advisory Committee: pneumococcal polysaccharide vaccine. MMWR Morb Mortal Wkly Rep 1989; 38:64-76.
13. Bartlett J, Mundy L. Community-acquired pneumonia. N Engl J Med 1995; 333:1618-24.
14. American College of Physicians Task Force on Adult Immunization, Infectious Disease Society of America. Guide for adult immunization. 3d ed. Philadelphia, PA: American College of Physicians, 1994.
15. Butler J, Hoffmann J, Cetron M, Elliott J, Facklam R, Breiman R. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's pneumococcal sentinel surveillance system. J Infect Dis 1996; 174:986-93.
16. Hoffman J, Cetron M, Farley M, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 333:481-6.
17. Breiman R, Butler J, Tenover F, Elliott J, Facklam R. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994; 271:1831-5.
18. Barile A, Driscoll T, Harley D, Habergerger R, Wallace M. Increasing incidence of penicillin-resistant Streptococcus pneumoniae [abstract no 734]. In: Program and abstracts of the Infectious Diseases Society of America 35th Annual Meeting (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 1997.
19. Gardner P, Schaffner W. Immunization of adults. N Engl J Med 1993; 328:1252-8.
20. Jorgensen J, Howell A, Maher L, Facklam R. Serotypes of respiratory isolates of Streptococcus pneumoniae compared with the capsular types included in the current pneumococcal vaccine. J Infect Dis 1991; 163:644-6.
21. Plouffe J, Breiman R, Facklam R. Bacteremia with Streptococcus pneumoniae. JAMA 1996; 275:194-8.
22. Robbins J, Austrian R, Lee C, et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983; 148:1136-59.
23. Patrick K, Wooley F. A cost-benefit analysis of immunization for pneumococcal pneumonia. JAMA 1981; 245:473-7.
24. Sisk J, Moskowitz A, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278:1333-9.
25. Willems J, Sanders C, Riddiough M, Bell J. Cost effectiveness of vaccination against pneumococcal pneumonia. N Engl J Med 1980; 303:553-9.
26. Marrie T. Community-acquired pneumonia. Clin Infect Dis 1994; 18:501-15.
27. Bates J, Campbell G, Barron A, et al. Microbial etiology of acute pneumonia in hospitalized patients. Chest 1992; 101:1005-12.
28. Naimark D, Krahn M, Naglie G, Redelmeier D, Detsky A. Primer on medical decision analysis: working with Markov processes. Med Decis Making 1997; 17:152-9.
29. Sonnenberg F, Beck J. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13:322-38.
30. Lehtomaki K, Leinonen M, Takala A, Hovi T, Herva E, Koskela M. Etiological diagnosis of pneumonia in military conscripts by combined use of bacterial culture and serological methods. Eur J Clin Microbiol Infect Dis 1988; 7:348-54.
31. Carroll D. Pneumonia in United States Marine Corps trainees. San Diego: San Diego State University, 1996:1-68.
32. Amundson D, Weiss P. Pneumonia in military recruits. Mil Med 1994; 159:629-31.
33. Austrian R. Pneumococcal pneumonia. Chest 1986; 90:738-43.
34. Gable C, Holzer S, Engelhart L, et al. Pneumococcal vaccine. JAMA 1990; 264:2910-5.
35. Austrian R, Douglas R, Schiffman G, et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Phys 1976; 89:184-94.
36. Austrian R. Random gleanings from a life with the pneumococcus. J Infect Dis 1975; 131:474-84.
37. Gold M, Patrick D, Torrance G, et al. Identifying and valuing outcomes. In: Gold M, Siegal J, Russell L, Weinstein M, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996; 82-123.
38. Lipscomb J, Weinstein M, Torrance G. Time preference. In: Gold M, Siegal J, Russell L, Weinstein M, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996; 214-6.
39. Smit P, Oberholzer D, Hayden-Smith S, Koornhof H, Hilleman M. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977; 238:2613-6.
40. Riley I, Andrews M, Howard R, et al. Immunization with a polyvalent pneumococcal vaccine: reduction of adult respiratory mortality in a New Guinea highlands community. Lancet 1977; 1:1338-41.
41. Simberkoff M, Cross A, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients. N Engl J Med 1986; 315:1318-27.
42. Gaillat J, Zmirou D, Mallaret M, et al. Clinical trial of an anti-pneumococcal vaccine in elderly subjects living in institutions [in French]. Rev Epidemiol Sante Publique 1985; 33:437-44.
43. Kouivula I, Sten M, Leinonen M, Makela P. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized single-blind population-based trial. Am J Med 1997; 103:281-90.
44. Ortqvist A, Hedlund J, Burman L, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998; 351:399-403.
45. Butler J, Breiman R, Campbell J, Lipman H, Broome C, Facklam R. Pneumococcal polysaccharide vaccine efficacy. JAMA 1993; 270:1826-31.
46. Fine M, Smith M, Carson C, et al. Efficacy of pneumococcal vaccine in adults. Arch Intern Med 1994; 154:2666-77.
47. Gabor E, Seeman M. Acute febrile systemic reaction to polyvalent pneumococcal vaccine. JAMA 1979; 242:2208-9.
48. Hilleman M, Carlson A, McLean A, Weibel R, Woodhour A. Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines. Rev Infect Dis 1981; 3(Suppl):S31-42.
49. Nelson K, Goldman J, Perlino C. Severe local reactions to pneumococcal vaccine. South Med J 1980; 73:264-5.
50. Schwartz JS. Pneumococcal vaccine: clinical efficacy and effectiveness. Ann Intern Med 1982:96(2);208-20.
51. Semel J, Seskind C. Severe febrile reaction to pneumococcal vaccine. JAMA 1979; 241:1792.
52. Uhl G, Farber J, Moench R, Friday K, Light R. Febrile reaction to pneumococcal vaccine. N Engl J Med 1978; 299:1318.
53. Centers for Disease Control and Prevention. Update: pneumococcal polysaccharide vaccine usage - United States. MMWR Morb Mortal Wkly Rep 1984; 33:273-6, 281.
54. Drug facts and comparisons. St. Louis, MO: Wolters Kluwer, 1997:2572-3.
55. Fryback D, Dasbach E, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993; 13:89-102.
56. Sisk J, Riegelman R. Cost effectiveness of vaccination against pneumococcal pneumonia: an update. Ann Intern Med 1986; 104:79-86.
57. Austrian R. Confronting drug-resistant pneumococci. Ann Intern Med 1994; 121:807-9.